HER2突变作为晚期乳腺癌的新兴目标
Giulia Bon1, Francesca Sofia Di Lisa2, Lorena Filomeno2
1Department of Research, Cellular Network and Molecular Therapeutic Target Unit, Diagnosis and Innovative Technologies, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Cancer science
|May 8, 2024
概括
激活HER2的突变驱动癌症和影响治疗. 新的试验探索 HER2 突变乳腺癌疗法,以这些特定突变为目标,以改善结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 激活HER2 (人类表皮生长因子受体2) 突变是各种癌症的关键驱动因素.
- 在乳腺癌中,这些突变在HER2非增强转移性疾病中被发现,并且代表了对HER2基因增强的替代方案.
- 获得的HER2变化在治疗期间出现,有助于治疗耐药性.
研究的目的:
- 审查 HER2 瘤基因在乳腺癌中的结构组织和历史意义.
- 总结HER2突变在治疗耐药性的频率,功能相关性和作用.
- 介绍正在进行的临床试验,研究HER2突变乳腺癌的新疗法.
主要方法:
- 临床前和临床研究的文献综述.
- 对HER2瘤基因结构和突变格局的分析.
- 针对HER2突变乳腺癌正在进行的临床试验的汇编.
主要成果:
- HER2突变赋予构成性激活,作为瘤驱动因素.
- 这些突变越来越被认为是对内分泌和HER2向疗法的耐药性机制.
- 许多临床试验正在评估针对HER2突变乳腺癌患者的HER2向药物.
结论:
- HER2突变是乳腺癌的关键治疗标,特别是在耐药性疾病中.
- 了解HER2突变的作用对于开发有效的治疗策略至关重要.
- 目前正在进行的试验为患有HER2突变乳腺癌的患者提供了希望,解决了针对性治疗的挑战.
更多相关视频
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
2.6K
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.2K
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
